Subscribe to RSS
DOI: 10.1055/s-0037-1615765
7E3 F(ab’)2, an Effective Antagonist of Rat αIIbβ3 and αvβ3, Blocks In Vivo Thrombus Formation and In Vitro Angiogenesis
Publication History
Received
17 August 2000
Accepted after resubmission
28 December 2000
Publication Date:
11 December 2017 (online)
Summary
Abciximab (c7E3 Fab, ReoPro®) blocks GPIIb/IIIa and αvβ3 and inhibits thrombotic and proliferative events only in humans and non-human primates. The bivalent F(ab’)2 fragment is an effective anti-thrombotic agent in canine models. In the present study, 7E3 F(ab’)2 was also found to bind to rat GPIIb/IIIa (KD = 27 ± 4 g/mL) and αvβ3 (KD = 9 ± 8 μg/mL), to block in vitro rat platelet aggregation (IC50 = 16 ± 6 μg/mL), and to inhibit αvβ3-mediated microvessel sprout formation in a rat aortic ring assay. Following administration of 7E3 F(ab’)2 (4 mg/kg) to rats, platelet aggregation was completely blocked for up to 6 h and thrombus formation in response to a rat abdominal aorta double crush injury was prevented. Effective chronic dosing was achieved with 6 mg/kg daily I.P. injections. In vitro mixing experiments indicated that 7E3 F(ab’)2 redistributed to unlabeled platelets in 2 h. Ex vivo, 7E3 F(ab’)2 was detected on platelets for up to 4 days after a single 4-mg/kg injection. These data suggest that 7E3 F(ab’)2 may be a useful agent to study the effects of GPIIb/IIIa and αvβ3 blockade in rat models of thrombosis and vascular disease.
-
References
- 1 The EPIC Investigators.. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
- 2 The EPIC Investigators.. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
- 3 The CAPTURE Investigators.. Randomized placebo-controlled trial of abciximab before and during intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-35.
- 4 Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and v 3 integrins. Circulation 1998; 98: 1085-91.
- 5 Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Inves 1985; 76: 101-8.
- 6 Jordan RE, Wagner CL, Macelli MA, Treacy G, Nedelman MA, Woody JN, Weisman HF, Coller BS. Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observation on the immunogenicity of c7E3 Fab in humans. In: Adhesion Receptors as Therapeutic Targets. Horton MA. ed. London: CRC Press; 1996: 281-305.
- 7 Knight DM, Wagner CL, Jordan RE, McAleer MF, Derita R, Fass DN, Coller BS, Weisman HF, Ghrayeb J. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol. 1995; 32: 1271-81.
- 8 Coller BS, Scuder LE. Inhibition of dog platelet function by in vivo infusion of F(ab’)2 fragments of a monoclonal antibody. Blood 1985; 66: 1456-9.
- 9 Bates ER, McGillem MJ, Mickelson JK, Pitt B, Mancini J. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation 1991; 84: 2463-9.
- 10 Coller BS. Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive therapy for coronary artery thrombolysis. Coron Artery Dis 1992; 3: 1016-29.
- 11 Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. The pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade. Circulation 1998; 97: 1680-8.
- 12 Kleiman NS, Raizner AE, Jordan RE, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activation peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995; 26: 1665-71.
- 13 Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 1990; 63: 115-22.
- 14 Helfrich MH, Nesbitt SA, Horton MA. Integrins on rat osteoclasts: characterization of two monoclonal antibodies (F4 and F11) to rat beta 3. J Bone Miner Res 1992; 7 (Suppl. 03) 345-51.
- 15 Christopoulos C, Mackie I, Lahiri I, Machin S. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa. Blood Coagul Fibrinolysis 1993; 4: 729-37.
- 16 Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88: 907-14.
- 17 Hjort PF, and Paputchis H. Platelet life span in normal, splenectomized and hypersplenic rats. Blood 1960; 15: 45-60.
- 18 White SM, Wagner JG, Roth RA. Effects of altered platelet number on pulmonary hypertension and platelet sequestration in monocrotaline pyrrole-treated rats. Toxicol Appl Pharmacol 1989; 99: 302-13.